SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn

Mark Connors; Barney S Graham; H Clifford Lane; Anthony S Fauci

doi:10.7326/M21-0111

SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn

Ann Intern Med. 2021 May;174(5):687-690. doi: 10.7326/M21-0111. Epub 2021 Jan 19.

Authors

Mark Connors¹, Barney S Graham², H Clifford Lane¹, Anthony S Fauci¹

Affiliations

¹ the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (M.C., H.C.L., A.S.F.).
² Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland (B.S.G.).

Abstract

As COVID vaccines roll out, internists and other health care providers are being turned to as trusted sources of information for patients and communities. Here, experts from NIAID outline the current state of knowledge regarding such vaccines. They contrast vaccine platforms, summarize clinical trial data regarding efficacy and safety, and comment on key questions including the ability of current vaccines to protect against infection and to decrease the prevalence of virus in the community.

MeSH terms

COVID-19 / immunology
COVID-19 / prevention & control*
COVID-19 Vaccines / immunology*
Clinical Trials as Topic
Humans
Immunogenicity, Vaccine
Pandemics / prevention & control
Patient Safety
Pneumonia, Viral / immunology
Pneumonia, Viral / prevention & control*
Pneumonia, Viral / virology
SARS-CoV-2 / immunology
United States
United States Food and Drug Administration
Vaccines, Synthetic / immunology*
Viral Vaccines / immunology
mRNA Vaccines

Substances

COVID-19 Vaccines
Vaccines, Synthetic
Viral Vaccines